A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. The results published by the New England Journal of Medicine are the first in coronvirus patients for remdesivir. All were given the drug through an IV for 10 days or as long as they tolerated it. A dozen patients had serious problems but it’s not clear whether they were from the drug or their disease. “It looks encouraging,” said Dr. Elizabeth Hohmann, an infectious disease specialist at Massachusetts General Hospital who is helping lead one of the studies testing the drug.

Source: The Standard April 11, 2020 01:41 UTC